Browsing Tag
Jeremy Bender
2 posts
Servier bets $2.5bn on pediatric cancer specialist Day One Biopharmaceuticals (Nasdaq: DAWN)
Servier is acquiring Day One Biopharmaceuticals for $2.5B to expand its rare oncology pipeline. Discover what the deal means for pediatric cancer drug innovation.
March 6, 2026
Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two…
February 23, 2021